BiotechTube

Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rotavirus

Conditions

Rotavirus, Gastroenteritis

Trial Timeline

Aug 1, 2008 → Aug 1, 2009

NCT ID
NCT00718237

About Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified)

Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) is a phase 3 stage product being developed by Merck for Rotavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT00718237. Target conditions include Rotavirus, Gastroenteritis.

What happened to similar drugs?

1 of 12 similar drugs in Rotavirus were approved

Approved (1) Terminated (1) Active (10)
✅RotaTeq™ (V260) + DTP-IPVMerckApproved
❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
🔄RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™MerckPhase 3
🔄Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered)MerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄Rotateq™ + Comparator: PlaceboMerckPhase 3
🔄Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00718237Phase 3Completed

Competing Products

14 competing products in Rotavirus

See all competitors
ProductCompanyStageHype Score
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
32
RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™MerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered)MerckPhase 3
40
RotaTeq (V260) + IPVMerckPhase 3
40
Rotateq™ + Comparator: PlaceboMerckPhase 3
40
RotaTeq™ (V260) + DTP-IPVMerckApproved
43
Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + PlaceboMerckPhase 1
21
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 3
40
V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
40
rotavirus vaccine, live, oral, pentavalent + PlaceboMerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 1
29
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) HexaMerckPhase 3
40
RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3
40
Rotarix + RotaTeqMerckPhase 3
40